Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) has been assigned a $18.00 price objective by equities researchers at Deutsche Bank AG in a note issued to investors on Friday. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price objective would indicate a potential upside of 33.63% from the company’s previous close.
VRX has been the topic of a number of other reports. BMO Capital Markets lifted their price objective on shares of Valeant Pharmaceuticals Intl to $21.00 in a research report on Wednesday, March 1st. Royal Bank of Canada lowered their price objective on shares of Valeant Pharmaceuticals Intl to $21.00 in a research report on Wednesday, March 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, February 9th. Guggenheim reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, February 7th. Finally, Jefferies Group LLC lowered their price objective on shares of Valeant Pharmaceuticals Intl from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $22.35.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 0.07% during mid-day trading on Friday, reaching $13.48. 16,351,922 shares of the company were exchanged. The stock has a 50 day moving average price of $10.48 and a 200-day moving average price of $13.78. Valeant Pharmaceuticals Intl has a 12 month low of $8.31 and a 12 month high of $32.74. The stock’s market capitalization is $4.69 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.93. The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.17 billion. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The company’s quarterly revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.08) EPS. Analysts predict that Valeant Pharmaceuticals Intl will post $3.89 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://sleekmoney.com/deutsche-bank-ag-reiterates-18-00-price-target-for-valeant-pharmaceuticals-intl-inc-vrx/1836168.html.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The shares were acquired at an average cost of $10.80 per share, for a total transaction of $108,000.00. Following the transaction, the director now directly owns 25,190 shares of the company’s stock, valued at $272,052. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pershing Square Capital Manage sold 18,114,432 shares of the business’s stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $11.00, for a total transaction of $199,258,752.00. The disclosure for this sale can be found here. Insiders purchased a total of 3,054,000 shares of company stock worth $33,103,280 over the last quarter. Insiders own 16.37% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. LeJeune Puetz Investment Counsel LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at $123,000. Gruss & Co. Inc. purchased a new position in shares of Valeant Pharmaceuticals Intl during the first quarter valued at $104,000. Financial Architects Inc increased its position in shares of Valeant Pharmaceuticals Intl by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. Harbor Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the first quarter valued at $110,000. Finally, Frontier Wealth Management LLC purchased a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at $149,000. Institutional investors and hedge funds own 64.34% of the company’s stock.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/deutsche-bank-ag-reiterates-18-00-price-target-for-valeant-pharmaceuticals-intl-inc-vrx/1836168.html
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.